News

Alivexis To Present at GTC 2025 Japan AI Day- 11 March, 2025

Alivexis Raises $0.7M USD Series D in Second Close- 03 March, 2025

PairMap: Revolutionizing Drug Discovery with Precise Energy Calculations- 12 February, 2025

Alivexis Raises $5.1M USD Series D in First Close- 07 January, 2025

Alivexis announces publication of a research article on its ground-breaking ModBind™ simulation technology- 20 December, 2024

Alivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo- 28 October, 2024

Cathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis～Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis～- 23 August, 2024

Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A- 21 June, 2024

Alivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target- 17 June, 2024

Joint Research on Novel Anti-Allergic Disease Drug Candidate Published by Alivexis, Inc. and University of Yamanashi- 11 April, 2024